Sinboda Biosciences: Pioneering AI-Driven Life Science Platforms to Reshape Microscale Manipulation and Detection
In the field of life science instruments, “chokehold” technologies and “import substitution” have long been focal points of the industry. However, as domestic substitution deepens, intensifying involutionary competition, coupled with the localization of manufacturing by European and American manufacturers and rising non-technical barriers, has made it difficult for domestically produced instruments to gain a foothold in the market.
“Think Different” is Apple’s innovation philosophy, and it also applies to the life sciences instrumentation industry. The key to competition lies not in being “better,” but in being “different”—independent innovation is the core driver for breaking through barriers and rewriting industry rules. Chinese enterprises must not only move beyond the limitations of “domestic substitution,” but also leverage disruptive technologies to reshape the global competitive landscape, evolving from world-class competitors into contributors to global innovation.
Xinbozhi Biotechnology (Zhejiang) Co., Ltd. (hereinafter referred to as “Xinbozhi”), established in August 2023, is a life sciences instrument R&D enterprise driven by disruptive innovation. Founded by a team of Cambridge PhDs and Zhejiang University Principal Investigators (PIs), Xinbozhi completed tens of millions of yuan in financing in December 2023 and officially launched its project and assembled its team in March 2024.
In less than a year, Xin Bozhi achieved full-process breakthroughs from technological R&D to market implementation, completingEstablishment of Three Core Technology Platforms, launchedTwo Life Science Instruments with World-Class Innovations：ScimaX Single-Cell Micro-Nano Manipulation SystemandSimdaX Single-Molecule Conformational Immunoassay Analyzer, used respectively in clinical settings forNon-Invasive Prenatal Diagnosis Using Fetal Nucleated Red Blood CellsandEarly Blood Tests for Alzheimer’s and Parkinson’s Diseases, marking the first step in reshaping the industry landscape.
Xin Bo to the Headquarters Building
Cell manipulation is central to life science research, yet existing technologies still face numerous challenges in high-precision cell sorting, microinjection, and the delivery of gene-editing components.
Although flow cytometry offers high-throughput screening capabilities, it struggles to meet the demands for non-destructive extraction of rare cells and high-precision screening. Manual microinjection relies heavily on operator experience, resulting in low efficiency and significant cell loss. While electroporation is widely used in gene editing, it exhibits strong randomness, a high damage rate, and extremely low homologous integration efficiency (1/10⁵). Furthermore, traditional techniques have limitations in accommodating both adherent and suspension cells, lacking automated and high-throughput solutions.
Xinbozhi Launches Disruptive InnovationScimaX Single-Cell Micro-Nano Manipulation Platform: Breaking the Limits of Traditional Cell Manipulation Technologies, Integrating Three Core Technologies—Proprietary High-End Optical Imaging Systems, AI Algorithms, and Dual-Arm Robotic Manipulators—Compatible with Both Adherent and Suspension Cells, Ushering in a New Era of AI-Driven Cell Injection and Sorting.
ScimaX integrates high-content imaging with AI-based image algorithms to precisely identify and analyze target cells. Furthermore, by leveraging dual-arm robotic manipulators with nanometer-level precision and AI-driven intelligent control algorithms, it enables non-destructive, efficient single-cell manipulation via simple mouse clicks, achieving an integrated solution for precise injection and sorting. The platform is equipped with a proprietary optical imaging module that supports high resolution and multi-channel compatibility, meeting diverse experimental requirements. Compared to traditional flow cytometry sorting, manual microinjection, and electroporation, ScimaX provides an intelligent, automated cell manipulation solution, delivering revolutionary breakthroughs in gene editing, cell therapy, and rare cell research, thereby advancing the development of precision medicine and life sciences.
ScimaX Single-Cell Micro-Nano Manipulation Platform
Xinbozhi has innovatively achieved true non-invasive diagnostic-grade screening by leveraging fetal nucleated red blood cell (FNRBC) extraction technology.This Technological BreakthroughFNRBCAddressing extraction challenges by integrating high-efficiency enrichment solutions into a single-cell micro-nano manipulation platform, enabling precise and efficient isolation of extremely rare cells from just 5 mL of maternal peripheral blood.FNRBC, covering the full spectrum of testing needs from 5 weeks of gestation through the third trimester.
FNRBC Prenatal Testing Offers Higher Accuracy and a Broader Detection Scope Compared to Traditional NIPT (Cell-Free Fetal DNA Testing). Traditional NIPT relies on fragmented cell-free DNA of placental origin, which cannot provide complete genetic information and is susceptible to placental mosaicism, posing risks of false-positive or false-negative results. In contrast, FNRBC testing directly isolates intact fetal cells carrying the full genome, enabling precise detection of genetic disorders such as chromosomal abnormalities, microdeletions, and microduplications. This approach avoids errors associated with placental mosaicism, achieving accuracy comparable to amniocentesis while eliminating the risk of miscarriage inherent to invasive procedures.
Xin Bozhi has developed a comprehensive non-invasive prenatal diagnosis solution for FNRBC,CoverageFNRBC ScreeningTechnical Platform andFNRBCDevelopment of a comprehensive product portfolio, including enrichment, identification, amplification, and library preparation kits, to bridge the technological gap between non-invasive screening and diagnosis. The project has established collaborations with an academician team and multiple maternal and child health hospitals, and has been selected for the National Health Commission’s Key R&D Program, driving non-invasive prenatal diagnosis into a new era of precision.
Xin Bozhi: Non-invasive Prenatal Diagnosis Using Fetal Nucleated Red Blood Cells
Xin Bozhi pioneered globally with the launch ofSimdaX 100, an in vitro diagnostic platform for immune complexes based on single-molecule imaging technology, breaks through the limitations of traditional immunoassays that only detect protein concentration. It pioneers the combined characterization of protein concentration and morphological information, providing a novel technical pathway for the diagnosis and research of complex diseases such as neurodegenerative disorders and cancer.
The degree of protein aggregation (e.g., α-synuclein, tau protein, and p53 protein) is a critical indicator of disease progression. Taking Parkinson’s disease as an example, large-scale clinical studies by Simbrius have demonstrated that measuring synuclein concentration alone fails to distinguish patients from healthy individuals, whereas analysis of its aggregation characteristics can accurately assess pathological progression and precisely identify patients. Traditional immunoassays (chemiluminescence, ELISA, and Simoa) detect only protein concentration and cannot characterize protein morphology, thereby limiting their application in early screening and precise diagnosis of complex diseases. The Simbrius SimdaX 100 overcomes this limitation by pioneering single-molecule imaging immunoassay combined with morphological information capture, offering a novel perspective on the correlation between protein aggregation and disease.
Xinbo’s Single-Molecule Conformation Technology represents a systematic innovation, encompassing a series of technological breakthroughs in imaging resolution, autofocus, experimental workflows, reaction systems, laboratory consumables, and AI-driven analysis. It successfully achieves ultra-high resolution with individual fluorescent molecules as the smallest detection unit, attaining femtogram-level sensitivity. This enables direct visualization of protein aggregation levels and precise differentiation between monomers and aggregates.Suitable for diverse sample types, including plasma, serum, and cerebrospinal fluid; applied to early screening, therapeutic efficacy assessment, drug development, and biomarker discovery for diseases such as Parkinson’s disease, Alzheimer’s disease, and cancer.This innovative technology provides a novel tool for precision medicine in immunoassays, steering in vitro diagnostics toward a more precise future.
SimdaX: Single-Molecule Conformational Immunoassay Platform
“Those who can bring breakthrough changes to the industry are never imitators, but innovators.” This isChen Xiaohua, Founder of Xinbozhibelief. As a Ph.D. in Economics from the University of Cambridge, Dr. Chen Xiaohua’s background is not in life sciences; however, her economic training fostered unique logical thinking and an end-goal-oriented mindset. Upon returning to China to teach at Zhejiang University, she keenly recognized the development potential of life science technology platforms and broad health applications. Sharing immediate synergy with her Cambridge alumnus, Dr. Li Bing, and her Zhejiang University colleague, Professor Yang Liangjing, she co-founded SimberZhi Biotechnology, adhering to the core philosophy of “meeting unmet clinical and health needs through technological innovation.”
From Xin Bo to Dr. Li Bing, Chief Technology OfficerDr. Bing Li holds a Ph.D. in Chemistry from the University of Cambridge and previously served as a Research Fellow at the university. He studied under Professor Sir David Klenerman, the inventor of next-generation sequencing technology, focusing on the application of single-molecule imaging in neurodegenerative diseases, which laid a solid foundation for Simbrix’s single-molecule conformation technology. During his collaboration with the University of Oxford on tumor T-cell research, he developed instruments for in situ manipulation of rare cells, establishing the cornerstone for Simbrix’s single-cell micro-nano manipulation technology. Dr. Li possesses an interdisciplinary background spanning chemistry, biology, pathology, and instrument development, enabling him to accurately identify scientific research needs and translate them into efficient and practical technical solutions.
Xinbozhi Chief Scientist, Professor Yang Liangjing, currently a Principal Investigator (PI) at Zhejiang University and formerly a researcher at MIT, specializes in automation algorithms for biomedical robotics and image processing technologies. Professor Yang’s research encompasses endoscopic 3D reconstruction, robotic systems for combined ablation of liver tumors, and vision-guided micromanipulation platforms, driving frontier advancements in microscopic image processing and high-precision automated operations. He has leveraged his extensive expertise in this field to develop the core technology platform at Xinbozhi, significantly enhancing the company’s world-class capabilities in algorithmic technologies.
The interdisciplinary founding team has laid a solid foundation for the development of Xinbozhi. Furthermore, the company has built core competencies in two key areas—
First, SimberZ has established an open innovation ecosystem that attracts top clinical and research experts to collaborate, closely aligning foundational technological innovations with clinical needs. By taking real-world demands as the starting point for R&D, it drives systematic breakthroughs in practical application.
Second, Sinberzhi possesses robust engineering and productization capabilities. It has assembled a team of engineers with over ten years of industry experience, successfully overcoming a series of challenges in instrument and reagent development without relying on existing templates, thereby enabling the most efficient translation of technological innovations into market-ready products.
Since Xin Bozhi returned to China and landed in March 2024,In less than a year,we successfully developed and launched two life science technology platforms with world-class innovations—the Single-Cell Micro-Nano Manipulation Platform and the Single-Molecule Conformational Immunoassay Platform.Partnered with Sinopharm to achieve the first domestic sale, while simultaneously expanding into international markets.
The team has also completed large-scale clinical studies and end-to-end product development for nucleated red blood cell-based prenatal diagnosis and Parkinson’s disease projects. Over the next two years, we will achieve comprehensive clinical adoption of non-invasive prenatal diagnosis using nucleated red blood cells and screening and diagnostic solutions for neurodegenerative diseases, setting a new benchmark for global life science technology platforms and solutions.
Xinbozhi is committed to continuously providing the global life sciences sector with “unprecedented” technology platforms and solutions. By launching new breakthrough products annually, it aims to lead industry development and enhance brand competitiveness. Its two existing clinical projects represent Xinbozhi’s primary growth trajectory and hold substantial market potential. In the future, leveraging the advantages of its platform technologies, Xinbozhi will explore new applications in gene editing and tumor screening and diagnosis. Building upon its technology and application platforms, Xinbozhi will establish a data platform to drive the development of artificial intelligence algorithms and precision medicine, thereby creating a complete closed loop integrating technology, clinical health, and data.
Xinbozhi possesses robust capabilities for global technology expansion, accelerating its worldwide strategic layout and driving its technologies into international markets, particularly achieving reverse technology exports to developed countries. By deeply cultivating the global market, Xinbozhi will not only bring cutting-edge technologies to the international life sciences sector but also promote global technological innovation and advancements in healthcare through cross-border collaboration and applications.